Synchron paused its Stentrode BCI trial after a lead performance issue, saying the move was voluntary and not an FDA mandate.
Zimmer Biomet raised its FY 2026 financial guidance after reporting broad-based Q3 sales growth, driven by Hips, S.E.T., and ...
A new host-response blood test from Beckman Coulter and MeMed delivers bacterial-vs-viral results in 15 minutes, aiding ...
AAHKS warns Medicare's 2027 cuts to hip and knee replacement payments threaten procedure volumes, tech adoption, and medtech ...
FDA flagged safety alerts for Teleflex guidewires/catheters over coating particles and Intersurgical breathing tubes over ...
J&J's venture arm JJDC leads financing for Francis Medical's Vanquish prostate ablation system, supporting FDA PMA path for ...
The characterization of digital health technologies in vision care has transitioned from a theoretical taxonomy to a highly ...
Hyperfine's Q3 revenue topped cash burn for the first time, marking a major step toward capital efficiency and profitability.
The softer sales, along with reimbursement pressure in wound care, caused the London-based company to miss Wall Street ...
Forget Congress — the real medtech question for 2027 is whether hospital customers can still afford capital equipment ...
Boston Scientific's SIMPLAAFY data show aspirin alone or reduced-dose anticoagulation matches DAPT after Watchman Flx Pro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results